Skip to main content
. Author manuscript; available in PMC: 2022 Oct 26.
Published in final edited form as: Mol Cancer Ther. 2022 Mar 1;21(3):397–406. doi: 10.1158/1535-7163.MCT-21-0455

Figure 2.

Figure 2.

Effects of OKI-005 in vitro in TNBC and CRC cell lines. A) Anti-proliferative effects were assessed using the SRB assay. Cells were treated with OKI-005 at doses of 0–5 uM and proliferation was assessed at 72 hours. Absolute IC50 was calculated using GraphPad Prism software. B) Apoptotic effects were evaluated in 2 sensitive (CAL-120 and MDA-MB-231) and 2 resistant (HCC1395 and Hs578T) TNBC cell lines at 24 and 48 hours using the Caspase-Glo 3/7 assay. Cells were treated with OKI-005 doses 0–500 nM. C) Cell cycle analysis was performed in sensitive TNBC cell lines at 24 hours using Krishans staining followed by flow cytometry. * P < 0.05, ** P < 0.01 compared to ND. D) Effects of OKI-005 on protein acetylation and p21 in sensitive and resistant TNBC cell lines treated with OKI-005 for 24 hours. Total protein was extracted and assessed for expression of indicated proteins by immunoblotting.